Merav brings over 20 years of expertise in regulatory and clinical affairs, guiding medical device companies from early-stage development to successful market authorizations worldwide - including FDA clearance, CE marking under EU MDR, Health Canada approval, etc..

She has worked with start-ups as well as mid- and large-sized companies across the medical device industry, covering a wide range of therapeutic areas and device types — including cardiovascular, sleep medicine, in vitro diagnostics (IVD), multidisciplinary devices, combination products, and implants.

​

Before joining BioVision, Merav held a consulting role at BioMedical Strategy Ltd. and later served as Vice President at four start-up companies, leading end-to-end regulatory, clinical, and quality assurance initiatives. Her expertise spans the development of regulatory and clinical strategies, preparation of FDA submissions (510(k) and

Q-submissions), CE marking applications (Technical Files under MDD/IVDD/MDR), risk management, clinical investigation packages, usability studies, design control implementation, and pre-clinical testing programs.

​

Merav holds a PhD in Food Technology and Molecular Biology from the Hebrew University of Jerusalem and completed post-doctoral research in molecular genetics at the Weizmann Institute of Science.